The PharmTech team focused on its coverage of AAPS PharmSci 360 this week, conducting interviews with experts on a range of topics including formulation platforms, AI, amorphous solid dispersions, and animal studies.
News|Articles|May 4, 2015
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-05-06-2015
- Volume 11
- Issue 5
Capsugel Produces DPI Phase 2 Trial Supplies
Author(s)Pharmaceutical Technology Editors
Capsugel extends inhaled biotherapeutics delivery capability to Phase 2 clinical trials.
Advertisement
Capsugel announced on May 4 that the company has manufactured Phase 2 clinical trial supplies for a dry powder inhalation (DPI) formulation that delivers biotherapeutics to the lung. The supplies were manufactured by Bend Research, part of Capsugel’s Dosage Form Solutions business unit.
The inhaled dry-powder biotherapeutic, which was developed using particle engineering and spray-drying processing methods, is the first inhalation delivery therapy to be manufactured to Phase 2 scale at the company’s clinical trial manufacturing facility in Bend, OR.
The spray-dry technology and particle engineering provides a stable dry powder with improved aerosol performance and high collection efficiencies, the company reports. The DPI powders will be dosed in a Phase 2 clinical trial in 2015.
Capsugel reports that it will add commercial spray-drying capacity this year, enabling the company to manufacture DPI formulations at commercial scale.
Source:
Articles in this issue
over 11 years ago
Better Control of the API Supply Chain?over 11 years ago
Big Pharma Feeds Big CMO Growthover 11 years ago
Chinese API Manufacturer Warned for Data Integrity Issuesover 11 years ago
Mylan Recalls Injectables Due to Visible Particulate Matterover 11 years ago
FDA Releases Final Biosimilar Guidanceover 11 years ago
Vetter Serializes First Product for South Koreaover 11 years ago
IDT Biologika Vaccine Facility Recognizedover 11 years ago
SGS Completes Expansion at Mumbai Facilityover 11 years ago
Serialization: Deja Vu All Over Again?over 11 years ago
Gauging Change in Europe’s Sterile Manufacturing MarketAdvertisement
Related to this article
The agreement between CDER and OII with allow for coordinated marketing application assessments and inspections.
Shubhajit Paul, a senior research fellow in Boehringer Ingelheim’s Department of Material Analytical Sciences, spoke with PharmTech at AAPS PharmSci 360 to explain how tabletability prediction can be improved for roller-compacted formulations.
This week on PharmTech.com, experts discussed E&L suitability standards, rare disease treatment development, sourcing ingredient suppliers, the use of AI in quality control, and more.
Cole and Jaenisch dig into AI poisoning in pharma manufacturing, how it hides in plain sight, and who should be accountable for catching it.
Mahmood Majeed, ZS, explains why measurable AI outcomes in pharma supply chain and manufacturing jumped from 29% to 53%, and how GMP limits and GxP validation shape adoption.
BMS-Tempus, Roche-Zymeworks, and LGM-Sannova deals show what AI data, trispecifics, and nitrosamine testing mean for CMC, QA, and development teams.
Jane Zhang of ETCH Sourcing explains why geopolitics, transparency, and partnership now weigh as heavily as cost and quality when companies choose suppliers, in this episode of Ask the Expert, moderated by Susan J. Schniepp of Nelson Labs.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Why AI Model Updates Need Change Control: AAPS PharmSci 360 2026
2
From URS to Acceptance Evidence: Defining and Testing Interfaces in Pen Injector Assembly
3
USP 1074 Revises Excipient Safety: AAPS PharmSci 360 2026
4
PharmTech Weekly Roundup—October 23, 2026: CMC Considerations, Rare Disease Development, Standards Harmonization
5